These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30563908)

  • 1. Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.
    Kumar P; Capodagli GC; Awasthi D; Shrestha R; Maharaja K; Sukheja P; Li SG; Inoyama D; Zimmerman M; Ho Liang HP; Sarathy J; Mina M; Rasic G; Russo R; Perryman AL; Richmann T; Gupta A; Singleton E; Verma S; Husain S; Soteropoulos P; Wang Z; Morris R; Porter G; Agnihotri G; Salgame P; Ekins S; Rhee KY; Connell N; Dartois V; Neiditch MB; Freundlich JS; Alland D
    mBio; 2018 Dec; 9(6):. PubMed ID: 30563908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.
    Inoyama D; Awasthi D; Capodagli GC; Tsotetsi K; Sukheja P; Zimmerman M; Li SG; Jadhav R; Russo R; Wang X; Grady C; Richmann T; Shrestha R; Li L; Ahn YM; Ho Liang HP; Mina M; Park S; Perlin DS; Connell N; Dartois V; Alland D; Neiditch MB; Kumar P; Freundlich JS
    Cell Chem Biol; 2020 May; 27(5):560-570.e10. PubMed ID: 32197094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
    Slayden RA; Lee RE; Barry CE
    Mol Microbiol; 2000 Nov; 38(3):514-25. PubMed ID: 11069675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
    Mdluli K; Slayden RA; Zhu Y; Ramaswamy S; Pan X; Mead D; Crane DD; Musser JM; Barry CE
    Science; 1998 Jun; 280(5369):1607-10. PubMed ID: 9616124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
    Larsen MH; Vilchèze C; Kremer L; Besra GS; Parsons L; Salfinger M; Heifets L; Hazbon MH; Alland D; Sacchettini JC; Jacobs WR
    Mol Microbiol; 2002 Oct; 46(2):453-66. PubMed ID: 12406221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria.
    Kremer L; Dover LG; Morbidoni HR; Vilchèze C; Maughan WN; Baulard A; Tu SC; Honoré N; Deretic V; Sacchettini JC; Locht C; Jacobs WR; Besra GS
    J Biol Chem; 2003 Jun; 278(23):20547-54. PubMed ID: 12654922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.
    Lee AS; Lim IH; Tang LL; Telenti A; Wong SY
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2087-9. PubMed ID: 10428945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis.
    Slayden RA; Barry CE
    Tuberculosis (Edinb); 2002; 82(4-5):149-60. PubMed ID: 12464486
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Rudraraju RS; Daher SS; Gallardo-Macias R; Wang X; Neiditch MB; Freundlich JS
    Front Cell Infect Microbiol; 2022; 12():1008213. PubMed ID: 36189349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of KasA as the cellular target of an anti-tubercular scaffold.
    Abrahams KA; Chung CW; Ghidelli-Disse S; Rullas J; Rebollo-López MJ; Gurcha SS; Cox JA; Mendoza A; Jiménez-Navarro E; Martínez-Martínez MS; Neu M; Shillings A; Homes P; Argyrou A; Casanueva R; Loman NJ; Moynihan PJ; Lelièvre J; Selenski C; Axtman M; Kremer L; Bantscheff M; Angulo-Barturen I; Izquierdo MC; Cammack NC; Drewes G; Ballell L; Barros D; Besra GS; Bates RH
    Nat Commun; 2016 Sep; 7():12581. PubMed ID: 27581223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The β-ketoacyl-ACP synthase from Mycobacterium tuberculosis as potential drug targets.
    Singh V; Mani I; Chaudhary DK; Somvanshi P
    Curr Med Chem; 2011; 18(9):1318-24. PubMed ID: 21370994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite.
    Cunningham F; Esquivias J; Fernández-Menéndez R; Pérez A; Guardia A; Escribano J; Rivero C; Vimal M; Cacho M; de Dios-Antón P; Martínez-Martínez MS; Jiménez E; Huertas Valentín L; Rebollo-López MJ; López-Román EM; Sousa-Morcuende V; Rullas J; Neu M; Chung CW; Bates RH
    ACS Infect Dis; 2020 May; 6(5):1098-1109. PubMed ID: 32196311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Drug Design of Thiolactomycin Derivatives Against Mtb-KasA Enzyme to Inhibit Multidrug Resistance of Mycobacterium tuberculosis.
    Durairaj DR; Shanmughavel P
    Interdiscip Sci; 2019 Jun; 11(2):215-225. PubMed ID: 28856604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.
    Luckner SR; Machutta CA; Tonge PJ; Kisker C
    Structure; 2009 Jul; 17(7):1004-13. PubMed ID: 19604480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the role of Mycobacterium tuberculosis kasA gene mutations in isoniazid resistance.
    Sun YJ; Lee AS; Wong SY; Paton NI
    Clin Microbiol Infect; 2007 Aug; 13(8):833-5. PubMed ID: 17501974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against
    Zhu C; Liu Y; Hu L; Yang M; He ZG
    J Biol Chem; 2018 Oct; 293(43):16741-16750. PubMed ID: 30185616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.
    Schaeffer ML; Agnihotri G; Volker C; Kallender H; Brennan PJ; Lonsdale JT
    J Biol Chem; 2001 Dec; 276(50):47029-37. PubMed ID: 11600501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
    Unissa AN; Subbian S; Hanna LE; Selvakumar N
    Infect Genet Evol; 2016 Nov; 45():474-492. PubMed ID: 27612406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.
    Lee W; Luckner SR; Kisker C; Tonge PJ; Engels B
    Biochemistry; 2011 Jun; 50(25):5743-56. PubMed ID: 21615093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.